(-)-アポモルフィン·塩酸塩

4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-

HCID 9410CAS 314-19-2

基本情報

標準SMILES
CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3.Cl
InChIKey
SKYZYDSNJIOXRL-BTQNPOSSSA-N
分子式
C17H18ClNO2
平均分子量
303.8 g/mol
単同位体質量
303.1026065

名称と識別子

優先名称
4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-
IUPAC
(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol;hydrochloride
現地名
(-)-アポモルフィン·塩酸塩
英語名
Apomorphine hydrochloride
分子式
C17H18ClNO2
分子量
303.78

名称と別名

(-)-Apomorphine hydrochloride4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-RefChem:527368314-19-2(R)-(-)-Apomorphine hydrochlorideApomorphine chlorideApomorphinium chlorideApomorphine hydrochloride anhydrous(-)-Apomorphine (hydrochloride)9K13MD7A0DApomorphine.HCl
名称をさらに表示
(-)-アポモルフィン·塩酸塩(6aR)-5,6,6aβ,7-テトラヒドロ-6-メチル-4H-ジベンゾ[de,g]キノリン-10,11-ジオール·塩酸塩アポモルフィン·塩酸塩アポモルフィン塩酸塩(6aR)-5,6,6a,7-テトラヒドロ-6-メチル-4H-ジベンゾ[de,g]キノリン-10,11-ジオール·塩酸塩塩酸アポモルフィン(R)-(-)-アポモルヒネ塩酸塩APOMORPHINE HCLAPL-130277(?)-Apomorphine(r)-idUPRIMATAK251)KW-6500R(–)-APONSC 11442APL130277
R-(-)-Apomorphine hydrochlorideApomorphine SLBritajectNSC-11442Apomorphin hydrochloridpomorphini hydrochloridumApomorphinum hydrochloricum(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol;hydrochloride

データベース識別子

CAS
314-19-2
PubChem CID
9410
DTXSID
DTXSID5040598
UNII
9K13MD7A0D

物性

構造計算による物性

極性表面積
43.7 Ų
水素結合供与体数
3
水素結合受容体数
3
回転可能結合数
0
重原子数
21

実験および物理化学的性質

Collision Cross Section161.7 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
250 ℃ · >250℃
貯蔵温度
Store at RT
溶解性
1.08 mg/mL · ≥1.08 mg/mL in EtOH with ultrasonic; ≥12.9 mg/mL in DMSO; ≥5.12 mg/mL in H2O
外見
solid
EPAの化学物質情報
Apomorphine hydrochloride (314-19-2)

安全と法規制

危険有害性情報

Other Safety Information · 1 件

IMAP assessments - 4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride, (R)-: Environment tier I assessment;IMAP assessments - 4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride, (R)-: Human health tier I assessment

安全データ

tsca
TSCA listed
ridadr
3249
毒性
mmo-sat 20 mg/plate MUREAV 137,17,84
hazard_class
6.1(b)
packing_group
III

化学と産業

用途と製造

General Manufacturing Information4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-: INACTIVE
応用分野 · 2 件

使用Emetic.

一般的な説明Apomorphine hydrochloride,(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolone-10,11-diol hydrochloride (Apokyn), is awhite or off-white powder or crystal soluble in hot water(pKa=8.92). Apormorphine is an aporphine alkaloid of thebenzoquinoline class. Oral apomorphine is poorly absorbedand has a bioavailability of less than 4%. Upon subcutaneousadministration, apomorphine is completely absorbed. Within10 to 20 minutes, the maximum concentration of the drug isdistributed from the blood plasma to the CSF. Other potentialroutes of administration include continuous subcutaneous infusion,intravenous infusion, intranasal spray application,sublingual, and rectal administration.23 The agent is highlylipophilic in nature, allowing for rapid diffusion across theBBB after injection. Apomorphine has a short plasma halflife;however, clinical effects may last from 60 to 90 minutes.Apomorphine displays a significant degree of interpatientvariability in its pharmacokinetic profile. Studies of bothintravenous and subcutaneous injection routes found this variation was not attributable to body weight, age, gender,and duration of PD or L-DOPA dose/duration alone.Apomorphine is extensively metabolized. Hypothesizedroutes include sulfation, N-demethylation, glucuronidation,and oxidation. Subcutaneous injections of apomorphine arerenally and hepatically cleared, with the majority appearingto be renally cleared. Dosage adjustments are needed in bothliver and renal impairment. The activity of apomorphine isbelieved to be caused by stimulation of postsynaptic D1- andD2-type receptors within the caudate/putamen in the brain.Apomorphine is indicated for the acute, intermittent treatmentof hypomobility, “off” episodes (“end-of-dose wearingoff” and unpredictable on/off episodes) associated with advancedPD.

上流・下流製品情報

サプライヤー17 社

上海优宁维生物科技股份有限公司15921930842 15921930842 · [email protected]
武汉易泰科技有限公司上海分公司18930552037 · [email protected]
安耐吉化学&3A(安徽泽升科技有限公司)021-58432009 400-005-6266 · [email protected]
InvivoChem中国13549236410 · [email protected]
MedBio脉铂医药021-69568360 18916172912 · [email protected]

関連反応

5 件

関連ノート

読み込み中…